STERO Biotechs Ltd.
STERO BIOTECH LTD.
STERO Ltd., founded in 2017 and headquartered in Israel, is a clinical-stage company committed to the research and development of novel Cannabidiol (CBD) based treatments and solutions that will potentially benefit millions of patients by reducing the side effects and the need of steroid therapy.
STERO’s patent was granted! In the US on August 2018.
The patent exceptional strength is mainly due to its’ extremely wide coverage.
Stero has commenced 2 phase IIa clinical trials,
the 1st clinical trial stared on May 2019 on AutoImmune Hepatitis (AIH), while the 2nd clinical trial on Crohn’s disease (IBD) started in July 2019. additional clinical trial is planned for 2019 with even more indications in the pipeline.
A HUGE MARKET OPPORTUNITY:
STERO addresses a huge market opportunity. Steroids are the first line of treatment of many conditions, such as inflammatory and autoimmune diseases, including AutoImmune Hepatitis, rheumatoid arthritis, lupus, IBD, psoriasis and more.
REDUCING THE NEED FOR STEROIDS:
There is an urgent clinical unmet need to lower the dosage and the time period of Steroids administration.
STERO committed to the research and development of novel and improved Cannabidiol (CBD) based treatment solution.
STERO aims to solve this unmet need by offering CBD based treatment that will reduce Steroids’ dosage and therefore, their side effects.
STERO’s Solution will potentially benefit millions of patients suffering from the many known and common negative Implications of Steroids treatment.